Prime Editing-Installed Suppressor tRNAs for Disease-Agnostic Genome Editing

Abstract

Researchers developed a genome-editing strategy that targets nonsense mutations — a class of mutations that halt protein production too early and cause approximately one-third of all rare genetic diseases. Rather than designing custom edits for each specific mutation, this approach uses prime editing to install suppressor tRNA genes that can read through premature stop codons, restoring protein production. This makes it "disease-agnostic" — one system potentially treats multiple conditions.

Key Contributions

• Single prime editing system addresses ~30% of rare genetic diseases (those caused by nonsense mutations)
• Disease-agnostic approach — doesn't require custom editing strategy per disease
• Uses suppressor tRNAs: synthetic tRNA molecules that recognize premature stop codons and insert the correct amino acid, allowing the ribosome to read through instead of terminating
• Prime editing installs the suppressor tRNA gene into the genome, providing durable correction
• Published in Nature, November 2025
• David Liu received the 2025 Breakthrough Prize in Life Sciences for base editing and prime editing

Methodology

• Prime editing (developed by Liu lab, 2019) performs precise DNA edits without double-strand breaks
• The system writes a suppressor tRNA gene into the patient's genome
• This tRNA recognizes the premature stop codon (e.g., UGA, UAG, UAA) and inserts the correct amino acid
• Result: the mutated gene produces full-length, functional protein again

Results

• Demonstrated efficacy across multiple disease-causing nonsense mutations in human cells
• Covers all three stop codon types (UGA, UAG, UAA)
• First FDA-approved clinical trial of prime editing therapy began April 2024 (for chronic granulomatous disease)
• As of 2026: 19 clinical trials using base or prime editing are underway in 5 countries

Clinical Context

Prime editing improvements are dramatic:

• Error rates improved from 1 in 7 to approximately 1 in 101 (MIT research)
• ProPE system expands the prime editing window for previously inefficient targets
• Clinical roadmap published in Nature Reviews Bioengineering for translating base/prime editing to therapy

Limitations

• In vivo delivery remains a challenge — current approaches primarily use lipid nanoparticles targeting the liver
• Long-term effects of expressing suppressor tRNAs need monitoring (could they read through natural stop codons?)
• Manufacturing and regulatory pathway for personalized prime editing therapies still developing
• Clinical data from prime editing trials still early-stage (Phase 1)

Source: Prime editing-installed suppressor tRNAs by David Liu et al., Nature